SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Tilray Brands, Inc. engages as a consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis, Distribution, Beverage, and Wellness. The Cannabis segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage segment refers to the production, marketing, and sale of beverages. The Wellness segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Tilray Brands Inc

Tilray is trending as traders speculate on potential near-term catalysts related to cannabis rescheduling following comments from a key political figure. The community is closely watching for further developments, with some expecting a possible short squeeze and others debating the long-term fundamentals of the stock. Broader discussions include the potential impact on the cannabis industry, particularly for veterans and medical research.

AMC Robotics Corp. engages in developing and deploying AI-enabled robotics and smart security solutions, especially for warehouse automation, enterprise security, robotics patrol/incident-response and logistics automation. The company is headquartered in New York, NY.

AMC Robotics Corp.

AMCI is trending due to its recent surge, driven by excitement around its merger and potential in the robotics sector. Community members are actively discussing potential squeezes and price targets, while acknowledging the stock's volatility and low float. Bullish sentiment seems strong, with many hoping it can continue its momentum.

B. Riley Financial, Inc. engages in the provision of financial services and solutions to the capital raising and financial advisory needs of public and private firms. It operates through the following segments: Capital Markets, Wealth Management, Financial Consulting, Auction and Liquidation, Communications, and Consumer. The Capital Markets segment provides investment banking, corporate finance, research, wealth management, and sales and trading services to corporate, institutional, and high net worth clients. The Wealth Management segment offers retail brokerage, investment management, and insurance, and tax preparation services. The Financial Consulting segment focuses on a variety of specialized advisory services spanning bankruptcy, restructuring, turnaround management, forensic accounting, crisis and litigation support, appraisal and valuation, real estate, and operations management. The Auction and Liquidation segment deals with retail liquidation services. The Communications segment is composed of a portfolio of companies acquired for attractive risk-adjusted investment return characteristics. The Consumer segment includes Targus and the Brands investment portfolio. The company was founded in 1973 and is headquartered in Los Angeles, CA.

B. Riley Financial Inc

B. Riley Financial is trending due to a swing to profitability revealed in their Q2 earnings filing, which has sparked a surge in intraday trading. The community is discussing the potential for a turnaround squeeze, citing high short interest and a low float, drawing parallels to CVNA's past performance. Positive catalysts and debt restructuring are also key talking points.

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Pfizer Inc

Pfizer is trending as investors digest the company's weaker-than-expected 2026 outlook, particularly concerning COVID-19 drug demand and patent expirations. The community is actively discussing the potential for dividend cuts and the need for a new growth engine beyond COVID-related revenue. Some investors are taking a long-term view, focusing on the dividend yield and potential upside from the company's pipeline.

Luckin Coffee, Inc. engages in providing food and beverage items, and operates coffee retail stores. It has a pioneered a technology-driven retail network to provide coffee and other products of high quality, high convenience and high affordability to customers. The company manages pick-up stores, relax stores, and delivery kitchens. It also offers tea, snacks, and light meals through its mobile application. The company was founded by Zhi Ya Qian, Fei Yang and Jin Yi Guo on June 16, 2017 and is headquartered in Xiamen, China.

Luckin Coffee Inc - ADR

LKNCY is trending as investors discuss the recent price drop and potential reasons behind it, including lack of liquidity, possible selling by large shareholders, and concerns about transparency. The community is actively debating whether the drop presents a buying opportunity or signals deeper issues with the company, while also speculating on the potential for relisting and acquisitions.

Aldeyra Therapeutics, Inc. is a biotechnology company, which engages in research and development activities with related general business planning, including raising capital. It engages in the discovery of therapies designed to treat immune-mediated diseases. The company was founded by Thomas A. Jordan and John E. Dowling on August 13, 2004 and is headquartered in Lexington, MA.

Aldeyra Therapeutics Inc

ALDX is trending due to anticipation surrounding its upcoming FDA decision on its dry eye drug, reproxalap, with the community actively debating the likelihood of approval after previous setbacks. Discussions also involve the potential impact of a new RASP pipeline focus and a collaboration with AbbVie. Community members are weighing the potential for a short squeeze and a significant price movement based on the FDA's verdict.

Affirm Holdings, Inc. operates a platform for digital and mobile-first commerce. Its platform consists of three core elements: a point-of-sale payment solution for consumers, merchant commerce solutions, and a consumer-focused app. The company was founded by Max R. Levchin in 2012 and is headquartered in San Francisco, CA.

Affirm Holdings Inc - Ordinary Shares - Class A

Affirm Holdings Inc

Affirm is trending amid anticipation for upcoming earnings, with analysts projecting significant EPS growth. Community discussions include speculation on the potential impact of consumer credit trends and the company's valuation. The stock is exhibiting volatility, influenced by broader market sentiment and sector-specific news.

Biodexa Pharmaceuticals Plc is a drug delivery technology company. It is focused on the research and development of medicines for rare cancers, via both in-house programs as well as partnered programs. The firm's proprietary platform drug delivery technologies are Q-Sphera platform is a disruptive polymer microsphere technology, which is used for sustained release at the microscale to prolong and control the release of therapeutics over an extended period of time from weeks to months; Midasolve platform is an innovative nano saccharide technology, which is used to dissolve drugs at the nanoscale so that they can be administered in liquid form directly and locally into tumors; Midacore platform is an edge gold nanoparticle technology, which is used for targeting sites of disease at the nanoscale. The company was founded in 2000 and is headquartered in Cardiff, the United Kingdom.

Biodexa Pharmaceuticals Plc - ADR

Biodexa Pharmaceuticals Plc

BDRX is trending amidst discussions of its low float and potential for a squeeze, with some community members drawing comparisons to other recent high-momentum stocks. While some traders express bullish sentiment and anticipate further upside, others caution about potential dilution and high volatility. The stock's recent price action and ongoing community speculation are contributing to its current popularity.

Cipher Mining, Inc. operates as a Bitcoin mining ecosystem in the United States. The firm is developing a cryptocurrency business. The company was founded in 2021 and is headquartered in New York, NY.

Cipher Mining Inc

CIFR is trending amid fluctuating market sentiment and discussions around its AI infrastructure pivot, despite a lack of clear positive momentum. Community members are actively debating potential support levels and expressing frustration over perceived market manipulation, while noting the broader context of bitcoin volatility and data center sector trends. Discussions also involve analyst ratings and upcoming economic announcements that could impact the stock.

Nektar Therapeutics is a biotechnology company, which engages in the discovery and development of novel therapies which selectively modulate the immune system to treat autoimmune disorders. It also focuses on immunology and unparalleled expertise in polymer chemistry to create one-of-a-kind, highly-selective medicines with optimal therapeutic benefit. The company was founded in 1990 and is headquartered in San Francisco, CA.

Nektar Therapeutics

Nektar Therapeutics is trending amid discussions about its alopecia areata drug, rezpegaldesleukin, and its potential advancement to Phase 3 trials, despite some violations noted in earlier trials. The community is weighing the drug's efficacy and safety profile against existing treatments, while also considering Oppenheimer's positive analysis and price target increase. Some investors anticipate a settlement or buyout related to ongoing litigation with Eli Lilly.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Morgan Stanley initiated coverage on Duolingo (DUOL) with an 'Overweight' rating and $435 price target on the company's shares, The Fly reported.The vote of confidence from one of Wall Street’s biggest firms sent Duolingo shares up 10% to $370 on Wednesday. With 6.4% gains the previous day, it is the stock's best two-day run since August 2024."We see DUOL as a best-in-class consumer internet asset," Morgan Stanley analysts said in an investor note.They said the language learning app has the "rare combination" of rapid user growth, strong and expanding margins, and a clear generative artificial intelligence upside.The company also has a vast scope for monetization, they said, as it does not run ads, and the current monetization on the platform is about five times below mobile peers.Morgan Stanley also believes Duolingo's market of language learners is far from saturated."With each growth vector magnifying the others we see DUOL as a structural compounder and model a 26% 5-year revenue CAGR," it said.Earlier this month, JPMorgan reiterated Duolingo as its "Best Idea" in the online education sector, citing its strong prospects for user growth and monetization.&nbsp;&nbsp;In other corporate news, Duolingo said this week that it is adding a chess course, which includes the ability to play matches against an AI coach.On Stocktwits, retail sentiment turned to 'extremely bullish' from 'bearish' a day prior, and message volume 'high'.<figure class="image"><img style="aspect-ratio:811/180;" src="https://news.stocktwits-cdn.com/Screenshot_2025_04_24_at_8_58_08_AM_png_59cf966d29.webp" alt="Screenshot 2025-04-24 at 8.58.08 AM.png" width="811" height="180"><figcaption>DUOL sentiment and message volume as of April 23 | Source: Stocktwits</figcaption></figure>Several users posted comments suggesting that the backing from Morgan Stanley was a strong buying signal.<stembedurl>https://stocktwits.com/IN0V8/message/612453196</stembedurl><a href="https://stocktwits.com/symbol/DUOL">Shares</a> of Duoling are up over 14% year to date.For updates and corrections, email newsroom[at]stocktwits[dot]com.

A laptop keyboard and Duolingo on App Store displayed on a phone screen are seen in this illustration photo. (Photo by Jakub Porzycki/NurPhoto via Getty Images)

Duolingo 'Best-In-Class' Internet Stock, Says Morgan Stanley With 'Buy' Call: Retail Sentiment Flips To Extremely Bullish

The investment bank said Duolingo has the rare combination of rapid user growth, strong and expanding margins, and a clear generative artificial intelligence upside.

Equity

The investment bank said Duolingo has the rare combination of rapid user growth, strong and expanding margins, and a clear generative artificial intelligence upside.


Shares of Celsius Holdings Inc. (CELH) soared nearly 36% in after-hours trading Thursday after the energy drinks maker reported a quarterly earnings beat and agreed to acquire Alani Nutrition LLC for $1.8 billion, lifting retail sentiment.The transaction, which includes a mix of cash and stock including a potential $25 million earn-out, will combine “two growing, scaled brands in the U.S. energy drink category,” Celsius said in a statement. The transaction is expected to close in the second quarter of 2025.Founded in 2018, Alani Nu is a growing, female-focused brand that combined with Celsius, is expected to drive about $2 billion in sales.Separately, Celsius Holdings also reported better-than-expected earnings for its fourth quarter."Our record $1.36 billion full-year 2024 revenue reflects a solid year of performance, underscored by consumers' continued preference for our great-tasting, functional products. Celsius achieved exceptional milestones in 2024, which included contributing 30% of all category growth and increasing our category share by 160 basis points to 11.8%,” said John Fieldly, chairman and CEO of Celsius Holdings.Celsius’s Q4 adjusted earnings per share came in at $0.14, surpassing consensus estimates of $0.10, while Q4 revenue stood at $332.2 million, beating expectations of $326.19 million.Sentiment on Stocktwits inched up in the ‘extremely bullish’ zone with commenters cheering the earnings and the deal. Message volumes jumped to the ‘extremely high’ zone.<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2025_02_21_at_7_25_06_AM_79eee9c0c2.png" alt="Screenshot 2025-02-21 at 7.25.06 AM.png">One bullish commenter expects Celsius stock to reach $70 on Friday.<stembedurl>https://stocktwits.com/Baskinta1/message/605098008</stembedurl>The acquisition of Alani Nu will further strengthen Celsius' position in the “large, growing global energy category” which is projected to grow at a compounded annual growth rate of 10% from 2024 to 2029, the company noted.It is expected to boost cash EPS in the first year, with projected run-rate cost synergies of $50 million within two years.Retail sales of Alani Nu increased by 78% year-over-year as reported by Circana for the last-four-week period ended Jan. 26, 2025, the company noted. &nbsp;The purchase price for Alani Nu consists of $1.27 billion of cash and a $25 million earn-out and $500 million of newly issued restricted shares of Celsius Holdings common stock, representing about 8.7% pro-forma ownership.The cash payment consists of debt financing of $900 million and about $375 million of cash on hand, according to Celsius.Celsius stock is down 3% year-to-date.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Celsius Holdings Stock Soars On $1.8B Alani Nu Acquisition, Q4 Earnings Beat: Retail’s Exuberant

Sentiment on Stocktwits inched up in the ‘extremely bullish’ zone.

Shares of Celsius Holdings (CELH) slipped more than 5% on Wednesday after brokerage firm TD Cowen downgraded its stock to ‘hold’ from ‘buy,’ dampening retail sentiment.TD Cowen also cut its price target to $29 from $40, Fly.com reported. According to the report, TD Cowen’s retail tracking data showed a decline in the company's sales growth to 0.3% in the last four weeks ending January 11.With Celsius shares well below its highs, valuation multiples could contract further if the company goes "ex-growth," said the report, citing the analyst who warned against heightened competition.Morgan Stanley also highlighted NielsenIQ data that showed Celsius' year-over-year sales dipped in the last two weeks that were assessed, showing a 6% decline in the latest week.Morgan Stanley has kept its ‘Equal Weight’ rating and $42 price target.Sentiment on Stocktwits turned ‘bearish’ from ‘bullish’ a week ago. Message volumes rose to ‘extremely high’ levels from ‘normal.’<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2025_01_23_at_10_23_38_AM_d72c2aed5e.png" alt="Screenshot 2025-01-23 at 10.23.38 AM.png"> Last week, UBS analyst Peter Grom also cut the firm's price target to $39 from $45 with a ‘Buy’ rating, Fly.com reported. According to the analyst, sentiment about consumer staples continues to be bearish despite the sector underperformance compared to the broader market in recent years, with top and bottom line growth for majority of the group has underwhelmed compared to expectations.Celsius is a maker of premium lifestyle energy drinks under its namesake 'Celsisus' brand.Celsius stock is down 3.7% year-to-date.For updates and corrections, email newsroom[at]stocktwits[dot]com.

(Photo by John Parra/Getty Images for CELSIUS)

Celsius Stock Slips On Analyst Downgrade Amid Rising Competition: Retail Mood Dampens

Sentiment on Stocktwits turned ‘bearish’ from ‘bullish’ a week ago. 

iShares Trust - iShares ESG Select Screened S&P Mid-Cap ETF

Up more than 2%

Up 0–2%

Flat to down 2%

Down more than 2%

The S&P 500 is modestly lower so far in December, putting the Santa Claus rally in question. The Santa Claus rally refers to the market’s tendency to rise in the final weeks of the year—what do you expect from December 16 through December 31?

What do you expect the S&amp;P 500’s total return to be in the second half of December?

Stocktwits

What do you expect the S&P 500’s total return to be in the second half of December?

XJH
iShares ESG Screened S&P Mid-Cap ETF

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest XJH News

XJHiShares ESG Screened S&P Mid-Cap ETF